Todd Park to step down as CTO

Laura Pedulli | | Health Exec | Policy & Regulations

Todd Park will step down as U.S. chief technology officer (CTO) by the end of 2014, according to several news sources.

Although he will leave the post, he is expected to continue working for the White House—but in a different capacity. In his new role, he will recruit tech talent from Silicon Valley to fill government positions.

Park, who founded health IT firms athenahealth and Castlight Health, joined the Department of Health & Human Services (HHS) as CTO in 2009. He transitioned over to the White House as the federal CTO in 2012, becoming the second person ever to assume the role.   

During his tenure, Park worked on the rollout of HealthCare.gov, participated in releasing HHS data for public and private healthcare stakeholders, and worked to implement open source and API efforts, according to news sources.

The White House is anticipated to make a formal announcement about Park’s departure this week.

 

Laura Pedulli

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.